Itsva Dhata paPediatric Brain Tumors

A BATA FreeRelease 1 | eTurboNews | eTN
Avatar of Linda Hohnholz
rakanyorwa Linda Hohnholz

Kazia Therapeutics Limited yakazivisa dhata idzva rekiriniki rinoratidza mashandiro epaxalisib mumhando mbiri dzegomarara rehuropi hwehucheche hune hudiki hwakanyanya husina kuzadziswa.       

Idzi dhata inyaya yezvinyorwa zvitatu zvakaratidzwa paMusangano Wepagore weAmerican Association for Cancer Research (AACR), wakaitirwa muNew Orleans, LA, kubva Kubvumbi 8 - 13, 2022.

Zvinyorwa zviviri nemasayendisiti anoshanda murabhoritari yeMubatsiri Muzvinafundo Jeffrey Rubens paJohns Hopkins University muBaltimore, MD, anotsanangura kushandiswa kwepaxalisib sekurapa kwemusana mugomarara rehuropi hunozivikanwa seatypical teratoid / rhabdoid tumors (AT/RT). Aka ndekekutanga kuti data yekuongorora paxalisib mune iyi fomu yegomarara reuropi yaunzwa, uye inovhura yakakosha chiratidzo chemushonga.

Yechitatu abstract, kubva kuboka rakasiyana revasayendisiti paJohns Hopkins University, inotungamirwa naMubatanidzwa Muzvinafundo Eric Raabe naDr Katherine Barnett, yakaratidza humbowo hwekubatana kwakasimba pakati pepaxalisib neimwe kirasi yekurapa cancer mune modhi ye diffuse intrinsic pontine glioma (DIPG) . Paxalisib yakamboratidza humbowo hwekuita muchirwere ichi, zvese se monotherapy uye musanganiswa nemhando dzinoverengeka dzekurapa cancer, uye iyo data nyowani inowedzera kusimbisa kugona kwayo muchirwere ichi chakanyanya kuoma.

Nheyo dzinokosha

• AT/RT igomarara remuuropi risingawanzowaniki rinobata vacheche nevana vadiki. Iko hakuna FDA yakatenderwa mishonga yeAT/RT uye iripo nzira dzekurapa dzakashomeka. Vashoma pane mumwe muvarwere vashanu vanorarama makore anopfuura maviri kubva pakuongororwa.

• Data kubva murabhoritari yaProfessor Rubens inoratidza kuti nzira yePI3K inowanzoitwa muAT/RT, uye kuti kurapwa nepaxalisib chete kunoshanda mumhando dzepreclinical dzechirwere. Uyezve, kusanganiswa neRG2822, HDAC inhibitor, kana TAK580, MAPK inhibitor, inoita seinowedzera kurarama kana ichienzaniswa nekurapa monotherapy.

• DIPG igomarara remuuropi risingawanzooneki muvana vadiki nevayaruki. Iko hakuna FDA inotenderwa mishonga, uye avhareji yekurarama hupenyu kubva mukuongororwa kazhinji avhareji inotenderedza mwedzi gumi.

• Zvakamboitika kubva kuzvikwata zvakawanda zvevaongorori, uye kunyanya kubva kuchikwata chaProfessor Matt Dun kuHunter Medical Research Institute, zvakaratidza kuti paxalisib inoshanda zvakanyanya muDIPG uye inosanganiswa nesynergistically nemishonga yakawanda yegomarara.

• Data kubva kuna Drs Raabe naBarnett uye vaanoshanda navo vanozivisa imwe itsva yekuwedzera kurapwa musanganiswa, ine HDAC inhibitor RG2833, iyo inoratidza humbowo hwekubatana kwakasimba mu preclinical modhi yeDIPG.

Mukuru weKazia, Dr James Garner, vakawedzera kuti, “Iri idata rinovimbisa zvikuru, uye tinotenda kuchikwata cheJohns Hopkins netsvakiridzo iyi yakakosha uye inokurudzira. Paxalisib yatove nyaya yekuenderera mberi kwechikamu chechipiri chekiriniki kuyedzwa muDIPG uye diffuse midline gliomas (NCT05009992) uye iyi data nyowani inoratidza zvingangoita zvakakura mashandisirwo emushonga muhucheche hwegomarara rehuropi. Tinotarisira kushanda nechikwata cheJohns Hopkins, uye nevamwe vatinoshanda navo nevapi vemazano, kuongorora mikana iyi zvakare. "

Nezvomunyori

Avatar of Linda Hohnholz

Linda Hohnholz

Editor mukuru we eTurboNews yakavakirwa muTN HQ.

Subscribe
Notify of
muenzi
0 Comments
Inline feedbacks
Ona zvese zvataurwa
0
Ndingade pfungwa dzako, ndapota taura.x
Govera ku...